Information Provided By:
Fly News Breaks for May 12, 2015
DEPO
May 12, 2015 | 12:44 EDT
Roth Capital views the post-earnings pullback in shares of Depomed as an overreaction. Roth points out that while higher spending could hurt earnings, it could also increase the company's revenue ramp. The firm expects Nucynta prescriptions to turn momentum positive again and reiterates a Buy rating on Depomed. It lowered its price target for shares to $28.50 from $30. Janney Capital just upgraded Depomed to Buy amid today's pullback.
News For DEPO From the Last 2 Days
There are no results for your query DEPO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.